Compositions and methods of use of phorbol esters for the treatment of stroke
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.
1. A method for alleviating or treating impaired mobility as an effect or symptom of stroke in a mammalian subject comprising administering an effective amount of phorbol ester of Formula I or a pharmaceutically-acceptable salt, isomer, or enantiomer, thereof to said subject
wherein R1 and R2 are selected from the group consisting of hydrogen, hydroxyl,
wherein the alkyl group contains 1 to 15 carbon atoms,
wherein the lower alkenyl group contains 1 to 7 carbon atoms,
and R3 is hydrogen or
2. The method of claim 1 , wherein R1 or R2 is
the remaining R1 and R2 is
and R3 is hydrogen.
3. The method of claim 1 , wherein the phorbol ester is phorbol 13-butyrate, phorbol 12-decanoate, phorbol 13-decanoate, phorbol 12,13-diacetate, phorbol 13,20-diacetate, phorbol 12,13-dibenzoate, phorbol 12,13-dibutyrate, phorbol 12,13-didecanoate, phorbol 12,13-dihexanoate, phorbol 12,13-dipropionate, phorbol 12-myristate, phorbol 13-myristate, phorbol 12,13,20-triacetate, 12-deoxyphorbol 13-angelate, 12-deoxyphorbol 13-angelate 20-acetate, 12-deoxyphorbol 13-isobutyrate, 12-deoxyphorbol 13-isobutyrate-20-acetate, 12-deoxyphorbol 13-phenylacetate, 12-deoxyphorbol 13-phenylacetate 20-acetate, 12-deoxyphorbol 13-tetradecanoate, phorbol 12-tigliate 13-decanoate, 12-deoxyphorbol 13-acetate, phorbol 12-acetate, or phorbol 13-acetate.
4. The method of claim 1 , wherein the phorbol ester is 12-O-tetradecanoylphorbol-13-acetate.
5. The method of claim 1 , further comprising administering at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation or coordinate treatment regimen with said phorbol ester of Formula I.
6. The method of claim 5 , wherein the at least one secondary or adjunctive therapeutic agent is administered to said subject in a coordinate administration protocol, simultaneously with, prior to, or after, administration of said phorbol ester to said subject.
7. The method of claim 5 , wherein the at least one secondary or adjunctive therapeutic agent is tissue plasminogen activator, an anticoagulant, a statin, fibrate, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitor, beta-blocker, anti-platelet agent, calcium channel blocker, or diuretic.
8. The method of claim 1 , further comprising surgical intervention in combination with phorbol ester of Formula I to treat or prevent effects of stroke in said subject.
9. The method of claim 8 , wherein the surgical intervention is a carotid endarterectomy, angioplasty, stent placement, craniotomy, insertion of a pacemaker, implantation of a defibrillator, replacement of valves, coronary artery bypass, heart transplantation, endovascular coil emobilization, or patent foramen ovale closure.
10. The method of claim 1 , wherein the impaired mobility is the effect of stroke.
11. The method of claim 1 , wherein the impaired mobility is the symptom of stroke.